Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Three Years On, Strategy Under CEO O’Day Is Unchanged
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
